Olanzapine (Zyprexa Relprevv) vs Quetiapine (Seroquel)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Olanzapine (Zyprexa Relprevv)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00088478 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial of 402 patients. All three tested doses of the long-acting olanzapine injection produced a significantly greater reduction in psychiatric symptom severity (PANSS) than placebo.
Reported efficacy
Demonstrate superiority of IM olanzapine depot 300 mg/2 weeks, 405 mg/4 weeks, and 210 mg/2 weeks dosages compared with placebo in the treatment of patients with schizophrenia: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each). (met)
Result source: NCT00088478
Quetiapine (Seroquel)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00305422 · Phase 3 · completed
The study was randomized and double-blinded with an active risperidone comparator, but its small sample of 45 participants limits the strength of the evidence. The primary comparison was not reported, and the primary focus included cognitive and functional brain-activation measures rather than a clearly specified hard clinical endpoint.
Next expected readout: February 2032 · NCT07152184 (registry estimate)
Reported efficacy
Clinical efficacy of both neuroleptics, especially with regard to cognitive deficits and functional brain activation between baseline and week 12: Global cognition improved vs baseline at week 12 on quetiapine (p<0.01) and risperidone (p<0.05).
Result source: NCT00305422
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Olanzapine (Zyprexa Relprevv) | Quetiapine (Seroquel) |
|---|---|---|
| PANSS total, change | —Not posted · NCT00088491 | -24 vs -15.9−8.1 vs placeboNCT018103801 other result
|
| CGI-S, change | -0.4 vs -0.3vs Oral OlanzapineNCT00320489 | -1.4 vs -0.9−0.5 vs placeboNCT018103801 other result
|
| PANSS response | —Not posted · NCT00088491 | 62.7% vs 32.1%+30.6 vs placeboNCT01810380 |
| PSP, change | —Not posted · NCT00088491 | 15.3 vs 9.4+5.9 vs placeboNCT01810380 |
| Relapse (% of patients) | 20.1% vs 18.5%vs Oral OlanzapineNCT00320489 | —Not posted · NCT00305422 |
PANSS total, change
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Quetiapine (Seroquel)
- -24 vs -15.9−8.1 vs placeboNCT01810380
1 other result
- -33.4 vs -35.9 NCT00882518
CGI-S, change
- Olanzapine (Zyprexa Relprevv)
- -0.4 vs -0.3vs Oral OlanzapineNCT00320489
- Quetiapine (Seroquel)
- -1.4 vs -0.9−0.5 vs placeboNCT01810380
1 other result
- -1.8 vs -2.1 NCT00882518
PANSS response
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Quetiapine (Seroquel)
- 62.7% vs 32.1%+30.6 vs placeboNCT01810380
PSP, change
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Quetiapine (Seroquel)
- 15.3 vs 9.4+5.9 vs placeboNCT01810380
Relapse (% of patients)
- Olanzapine (Zyprexa Relprevv)
- 20.1% vs 18.5%vs Oral OlanzapineNCT00320489
- Quetiapine (Seroquel)
- —Not posted · NCT00305422
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Olanzapine (Zyprexa Relprevv): 4 of 4 rows · Quetiapine (Seroquel): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Olanzapine (Zyprexa Relprevv) | Quetiapine (Seroquel) |
|---|---|---|
| Dropout rate | 54.9%a NCT00320489 · Phase 3 · monotherapy show 1 more result60.3% NCT00088465 · Phase 3 · registry result, not featured evidence | —Seroquel IRa NCT01213836 · Phase 4 · registry result, not featured evidence show 7 more results—Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 30.4% NCT00156715 · Phase 4 · registry result, not featured evidence —Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence 20.8%Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence 19.4% NCT00882518 · Phase 3 · registry result, not featured evidence 37.8% NCT00227305 · Phase 3 · registry result, not featured evidence 16.7% NCT00642369 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 9.8%a NCT00320489 · Phase 3 · monotherapy show 1 more result8.3% NCT00088465 · Phase 3 · registry result, not featured evidence | —Seroquel IRa NCT01213836 · Phase 4 · registry result, not featured evidence show 7 more results—Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence — NCT00156715 · Phase 4 · registry result, not featured evidence —Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence 2.6%Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence 4.6% NCT00882518 · Phase 3 · registry result, not featured evidence 10.5% NCT00227305 · Phase 3 · registry result, not featured evidence 6.7% NCT00642369 · Phase na · registry result, not featured evidence |
| Serious AEs | 9.5%a NCT00320489 · Phase 3 · monotherapy show 1 more result18.3% NCT00088465 · Phase 3 · registry result, not featured evidence | 0%Seroquel IRa NCT01213836 · Phase 4 · registry result, not featured evidence show 7 more results0%Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 18.8% NCT00156715 · Phase 4 · registry result, not featured evidence 1.3%Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence —Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence 0% NCT00882518 · Phase 3 · registry result, not featured evidence 12.1% NCT00227305 · Phase 3 · registry result, not featured evidence 0% NCT00642369 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | show 1 more resultweight increased 14.4% anxiety 9.7% insomnia 9.7% NCT00088465 · Phase 3 · registry result, not featured evidence | a somnolence 3.2% delusion 1.6% dizziness 1.6% NCT01213836 · Phase 4 · registry result, not featured evidence show 5 more resultspsychotic disorder 1.6% sedation 1.6% sleep disorder 1.6% NCT01213836 · Phase 4 · registry result, not featured evidence dry mouth 43.8% sedation 43.8% increased appetite/weight gain 31.3% NCT00156715 · Phase 4 · registry result, not featured evidence somnolence 22.2% (placebo 5%) weight increased 13.1% (placebo 3.7%) dizziness 11.8% (placebo 0.6%) NCT01810380 · Phase 3 · registry result, not featured evidence constipation 25% dizziness 14.3% insomnia 12.8% NCT00882518 · Phase 3 · registry result, not featured evidence somnolence 30.3% increased appetite 20% sedation 18.9% NCT00227305 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olanzapine (Zyprexa Relprevv)
+ 14 further endpoints in the CSV export.
Quetiapine (Seroquel)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 11 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (Zyprexa Relprevv)'s landscape · Quetiapine (Seroquel)'s landscape